Abbisko and Lilly’s Deepening Tie Shows How Oncology’s Real M&A Is Happening in the Shadows
Abbisko Therapeutics expands its Lilly R&D collaboration, revealing how mid-stage oncology biotechs are trading equity upside for pipeline survival...
Eli Lilly
Lilly’s $7.8B Centessa Bet Signals a New M&A Playbook: Buy the Mechanism, Not the Molecule
Lilly's $7.8B Centessa acquisition, approved by UK High Court on June 22, reveals Big Pharma's new M&A logic: own...
Lilly’s $2.3B JAK2 Bet Just Showed Its First Cards — and the Myelofibrosis Market Won’t Be the Same
Lilly's AJ1-11095 hit 70% spleen volume reduction in post-ruxolitinib patients at EHA 2026, threatening Incyte's $1.5B ruxolitinib franchise with...
The Triple Threat: Incretin Multi-Agonists Are About to Redraw the $77B Obesity Map
Nature Reviews flags incretin multi-agonist reversal of obesity and diabetes — Lilly's retatrutide Phase 3 data signals the GLP-1...
Novo Nordisk’s 20.7% Weight Loss Number Changes the GLP-1 Rulebook
Novo Nordisk's Wegovy 7.2 mg CHMP approval delivers 20.7% mean weight loss — rewriting competitive benchmarks for Eli Lilly's...
Lilly’s $300M CrossBridge Bet Isn’t About ADCs — It’s About Buying the Next Decade of Oncology Pricing Power
Eli Lilly's $300M acquisition of CrossBridge Bio targets dual-payload ADCs — a manufacturing cost doubler that signals a bold...
The GLP-1 Wars Are Over — The Incretin Platform Wars Have Begun
Orforglipron's 72-week Phase 3 data, SURMOUNT-5's head-to-head verdict, and Roche's oral small molecule push signal a $87B market restructuring...
Lilly’s Oral Pivot: Foundayo’s Maintenance Data Isn’t a Scientific Win — It’s a Market Access Weapon
Lilly's ATTAIN-MAINTAIN trial shows Foundayo maintains weight loss after injectable GLP-1s — a $42B market's access problem just found...
AI Rewires Drug Discovery’s Economics, Infrastructure, and Biology Itself
At BIO-Europe Spring 2026, leaders from Eli Lilly, Schrödinger, Boltz, Bioptimus, and Sofinnova Partners convened to diagnose how foundation...
Lilly’s $6.3B Sleep Bet Isn’t About Sleep — It’s About Owning the Next Neuroscience Platform
Eli Lilly just paid $6.3 billion upfront for Centessa Pharmaceuticals and its sleep disorder pipeline. The price looks steep...